OOIR: Observatory of International Research

Papers

(The H4-Index of Vaccine is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003–2024)	272
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom	172
Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods	161
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants	121
“Fighting the pandemic!” Western Australian pharmacists’ perspectives on COVID-19 vaccines: A qualitative study	117
Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirköy strain sheep pox vaccine under field conditions	115
Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination	110
Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates	93
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination	93
Erratum to “Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals” [Vaccine 41(37) (2023) 5469-5476]	90
Cost of illness due to pertussis in adults ≥50 years of age in the United Kingdom	88
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study	85
Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study	85
Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation	82
The social lives of the SARS-CoV-2 vaccines: A qualitative study of vaccine understandings and decision-making among people of Black ethnicities in London, UK	81
Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS coloni	81
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental chal	79
Pre-implementation evaluation for an HPV vaccine provider communication intervention among primary care clinics	75
Nationwide rollout of HPV vaccination in Nepal: Early key insights	72
Assessing commutability of the first WHO International Standard for antiserum to respiratory syncytial virus	72
Timeliness and completeness of serial routine vaccinations among 8062 rural children in southwest China during the COVID-19 pandemic: A multi-stage stratified cluster sampling survey in 1094 villages	72
Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders	72
Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study	70
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine	69
Editorial Board/Aims and Scope	67

Editorial Board/Aims and Scope	63
TAK − 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice	62
Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process	60
Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus	60
Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations	58
Systematic review of pro-equity strategies to improve vaccination among priority populations	57
The Brucella abortus A19ΔfeuPΔfeuQ double-mutant is highly attenuated and confers protection in BALB/c mice	56
Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis	56
Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines	56
U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic	55
Erratum to “Motivational interviewing and vaccine acceptance in children: The MOTIVE study” [Vaccine 40(12) (2022) 1846–1854]	55
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink	53
Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP)	53
Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season	52
Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models	51
Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents	51
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys	49
Effectiveness of the varicella vaccine in the real world, a matched case-control study	49
Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants	48
Advancing the use of vaccine impact modeling for immunization decisions in low- and middle-income countries	46
Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up	45
Examining the independent and interactive roles of intolerance of uncertainty in vaccination intent	45
Safety monitoring of health outcomes following influenza vaccination during the 2023–2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series	45